Uncategorized

Long-term health outcomes for lecanemab using simulation model and Phase 3 Clarity AD data published

BioArctic AB announced that its partner Eisai has published an article about long-term health outcomes of anti-amyloid-beta protofibril[1] antibody lecanemab in people living with mild cognitive impairment due to Alzheimer’s disease and mild AD using a disease simulation model in the peer-reviewed journal Neurology and Therapy.

Long-term health outcomes for lecanemab using simulation model and Phase 3 Clarity AD data published Read More »

Scroll to Top